ajou medical center
Tarafenacin Shows Success In South Korean Overactive Bladder Syndrome Trial
SALVAT and Kwang Dong Pharma have successfully completed a Phase IIb trial for Tarafenacin for the treatment of Overactive Bladder syndrome.



